Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (81-90 of 166) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancerM M Kim, P Allen, A M Gonzalez-Angulo, et al.
Clinical Breast Cancer|April 28, 2015
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerAna M Gonzalez-Angulo, Xiudong Lei, Richardo H Alvarez, et al.
Clinical Breast Cancer|January 28, 2014
Effect of age and race on quality of life in young breast cancer survivorsPhuong Khanh Morrow, Anita C Broxson, Mark F Munsell, et al.
Clinical Immunology (Orlando, Fla.)|March 26, 2018
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune responseTimothy J Vreeland, Jennifer K Litton, Na Qiao, et al.
Journal of Cancer|March 14, 2015
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Caimiao Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2026
Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansionNoor M Abdulkareem, Yan Jiang, Yuan Qi, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2008
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approachBeth M Beadle, Wendy A Woodward, Susan L Tucker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA MutationTapsi Kumar, Evie Hobbs, Fei Yang, et al.
The Oncologist|June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II StudyJennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
Pageof 17

Showing results (81-90 of 166) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2013
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancerM M Kim, P Allen, A M Gonzalez-Angulo, et al.
Clinical Breast Cancer|April 28, 2015
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerAna M Gonzalez-Angulo, Xiudong Lei, Richardo H Alvarez, et al.
Clinical Breast Cancer|January 28, 2014
Effect of age and race on quality of life in young breast cancer survivorsPhuong Khanh Morrow, Anita C Broxson, Mark F Munsell, et al.
Clinical Immunology (Orlando, Fla.)|March 26, 2018
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune responseTimothy J Vreeland, Jennifer K Litton, Na Qiao, et al.
Journal of Cancer|March 14, 2015
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Caimiao Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2026
Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansionNoor M Abdulkareem, Yan Jiang, Yuan Qi, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2008
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approachBeth M Beadle, Wendy A Woodward, Susan L Tucker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA MutationTapsi Kumar, Evie Hobbs, Fei Yang, et al.
The Oncologist|June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II StudyJennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.
Pageof 17